

Supplemental Tables and Figures

Table S1: Details of SARS-CoV-2 proteins

Protein	SARS-CoV-2 Sequence Length (AA)	Tags	Total Tag Length	Total Length	Expression
NTD	294 (14-307)	AviTag, His Tag	33	327	CHO
NCP	419 (1-419)	AviTag, His Tag	33	452	CHO
RBD-2	274 (319-592)	AviTag, His Tag	33	307	CHO
RBD-1	199 (329-527)	AviTag, His Tag	33	232	CHO
Full Length Spike (ST4)	1195 (14-1208)	T4 trimerization, AviTag, His Tag	62	1257	CHO
E484Q	274 (319-592)	AviTag, His Tag	33	307	CHO
UK variant (N501Y)	274 (319-592)	AviTag, His Tag	33	307	CHO
K417N/E484Q	274 (319-592)	AviTag, His Tag	33	307	CHO
South African variant (K417N/E484K/N501Y)	274 (319-592)	AviTag, His Tag	33	307	CHO
(Δ69-70/Δ144) UK NTD	291 (14-304)	AviTag, His Tag	33	327	CHO
South African variant (L18F/D80A/D215G/Δ242-244)	291 (14-304)	AviTag, His Tag	33	327	CHO

Table S2. Prevalence and titers of neutralizing antibodies (nAb) at study baseline and 6-month follow-up in SARS-CoV-2 positive, symptomatic unvaccinated children and adults.

	Children			Adults		
	Enrollment	6 months	P-value ^a	Enrollment	6 months	P-value ^a
% nAb positive (n)	100 (8)	87.5 (7)	0.32	81.3 (13)	50.0 (8)	0.03
n Ab titers	102 (70, 169)	42 (31, 53)	0.01	47 (27, 106)	11 (1, 51)	0.04

^a McNemar's test to compare prevalence of nAb; Wilcoxon matched-pairs signed-rank test to compare nAb titers

Table S3. Titers at study baseline and 6-month follow-up in SARS-CoV-2 PCR-positive, symptomatic unvaccinated children (n=8) and adults (n=16).

	Children			Adults		
	Enrollment		6 months	Enrollment		6 months
	Median (IQR)	Median (IQR)	P-value ^a	Median (IQR)	Median (IQR)	P-value ^a
Neutralizing antibody	102 (70, 169)	42 (31, 53)	0.01	47 (27, 106)	11 (1, 51)	0.04
Full Length Spike (ST4)	144033 (137270, 185275)	146482 (119264, 152687)	0.12	124611 (97707, 167777)	105213 (74523, 213269)	0.23
RBD1	81891 (70874, 94631)	26190 (15961, 42711)	0.01	26336 (10940, 83436)*	11146 (9969, 64302)	0.20
RBD2	137795 (129688, 148105)	97882 (52345, 115923)	0.01	106626 (71769, 232531)	60237 (22711, 129895)	0.03
NCP	152273 (140390, 264582)	123773 (87479, 141530)	0.03	176125 (122672, 361350)	112547 (73287, 142380)	0.003
NTD	119363 (107849, 137054)	109900 (83530, 128239)	0.09	69282 (23058, 124131)	60562 (20735, 136334)	0.16
E484Q	5708 (4828, 6674)	2134 (880, 2795)	0.01	1980 (426, 4710)*	516 (267, 3560)	0.03
N501Y	10214 (9634, 15763)	7860 (6729, 9684)	0.01	8196 (5721, 10486)	5203 (2513, 9395)	0.03
K417N/E484K/N501Y	3795 (1901, 5591)	801 (516, 2191)	0.01	584 (136, 1342)**	330 (68, 1565)	0.06
K417N E484Q	8099 (7402, 8895)	4583 (3111, 5879)	0.01	4310 (1429, 8049)	1524 (388, 6947)	0.02
Δ69-70/Δ144 NTD	9773 (9270, 10514)	8981 (7658, 10095)	0.01	7101 (3184, 13363)	4696 (2134, 10782)	0.12
L18F/D80A/D215G/Δ242-244	5985 (3910, 6690)	3770 (1628, 5838)	0.02	628 (286, 6198)	771 (316, 7021)	0.88

^a Wilcoxon matched-pairs signed-rank test.

*p<.05, **p<.01, Wilcoxon rank-sum test to compare adults vs. children at enrollment.

Table S4. Titers at study baseline and 6-month follow-up according to study cohort.

	Cohort	Enrollment		P ^a
		Median (IQR)	6 mo.	
Neutralizing antibody	SP+	102 (70, 169)	42 (31, 53)	0.01
	SP-	1 (1, 32)	1 (1, 1)	0.005
	AE	1 (1, 77)	1 (1, 33)	0.08
	ANE	1 (1, 1)	1 (1, 1)	0.32
Full Length Spike (ST4)	SP+	144033 (137270, 185275)	146482 (119264, 152687)	0.12
	SP-	2872 (273, 133838)	2903 (236, 63274)	0.41
	AE	3496 (307, 154355)	10044 (239, 123861)	0.10
	ANE	669 (317, 1825)	554 (304, 1250)	0.63
RBD1	SP+	81891 (70874, 94631)	26190 (15961, 42711)	0.01
	SP-	305 (162, 48222)	247 (99, 9919)	0.14
	AE	217 (77, 93334)	6740 (87, 21665)	0.35
	ANE	305 (118, 342)	234 (146, 542)	0.18
RBD2	SP+	137795 (129688, 148105)	97882 (52345, 115923)	0.01
	SP-	765 (354, 85065)	725 (363, 21926)	0.28
	AE	1432 (328, 145097)	8854 (649, 100402)	0.25
	ANE	629 (376, 2171)	599 (358, 2053)	0.63
NCP	SP+	152273 (140390, 264582)	123773 (87479, 141530)	0.03
	SP-	2577 (380, 133535)	760 (342, 58721)	0.13
	AE	6085 (334, 151857)	10500 (355, 97042)	0.13
	ANE	671 (270, 5285)	579 (320, 4751)	0.38
NTD	SP+	119363 (107849, 137054)	109900 (83530, 128239)	0.09
	SP-	128 (73, 46482)	90 (62, 10701)	0.08
	AE	279 (22, 136466)	3129 (28, 93801)	0.94
	ANE	72 (37, 119)	57 (30, 94)	0.28
E484Q	SP+	5708 (4828, 6674)	2134 (880, 2795)	0.01
	SP-	20 (20, 1242)	20 (20, 312)	0.04
	AE	25 (20, 5739)	38 (20, 1903)	0.13
	ANE	20 (20, 20)	20 (20, 20)	0.95
N501Y	SP+	10214 (9634, 15763)	7860 (6729, 9684)	0.01
	SP-	180 (29, 9831)	82 (21, 6649)	0.05
	AE	77 (36, 10362)	425 (104, 8473)	0.86
	ANE	141 (34, 331)	114 (38, 257)	0.16
K417N/E484K/N501Y	SP+	3795 (1901, 5591)	801 (516, 2191)	0.01
	SP-	24 (20, 437)	20 (20, 329)	0.001
	AE	21 (20, 2066)	20 (20, 607)	0.01
	ANE	20 (20, 20)	20 (20, 20)	0.32
K417N E484Q	SP+	8099 (7402, 8895)	4583 (3111, 5879)	0.01
	SP-	31 (20, 4726)	28 (20, 702)	0.04
	AE	31 (20, 7986)	101 (20, 5376)	0.19
	ANE	20 (20, 21)	20 (20, 31)	0.94
Δ69-70/Δ144 NTD	SP+	9773 (9270, 10514)	8981 (7658, 10095)	0.01
	SP-	41 (20, 6653)	33 (20, 3560)	0.02
	AE	39 (20, 10209)	69 (20, 8874)	0.83
	ANE	20 (20, 27)	20 (20, 20)	0.94
L18F/D80A/D215G/Δ242-244	SP+	5985 (3910, 6690)	3770 (1628, 5838)	0.02
	SP-	39 (20, 1032)	42 (20, 299)	0.06
	AE	51 (20, 4863)	46 (20, 3562)	0.56
	ANE	20 (20, 20)	20 (20, 23)	0.31

^a Wilcoxon matched-pairs signed-rank test

SP+, symptomatic, PCR+ (n=8); SP-, symptomatic , PCR- or not tested (n=27); AE, asymptomatic, known exposure (n=13); ANE, asymptomatic, no known exposure (n=19)

Table S5. Titers at study baseline and 6-month follow-up in SARS-CoV-2 PCR-positive, symptomatic adults who were unvaccinated (n=16) and vaccinated (n=7).

	No vaccination after visit 1 (n=16)			Vaccinated after visit 1 (n=7)		
	Enrollment	6 months	P ^a	Enrollment	6 months	P ^a
Neutralizing antibody	47 (27, 106)	11 (1, 51)	0.04	103 (1, 145)	1000 (385, 5000) †	0.02
Full Length Spike (ST4)	124611 (97707, 167777)	105213 (74523, 213269)	0.23	147063 (21665, 204154)	2013954 (1348154, 14422662) †	0.02
RBD1	26336 (10940, 83436)	11146 (9969, 64302)	0.20	79560 (716, 121739)	756835 (153278, 1528487) †	0.02
RBD2	106626 (71769, 232531)	60237 (22711, 129895)	0.03	145817 (378, 151965)	1432052 (763876, 2074017) †	0.02
NCP	176125 (122672, 361350)	112547 (73287, 142380)	0.003	141966 (470, 216876)	57193 (318, 152774)	0.02
NTD	69282 (23058, 124131)	60562 (20735, 136334)	0.16	90059 (200, 133184)	1129327 (690146, 2086326) †	0.02
E484Q	1980 (426, 4710)	516 (267, 3560)	0.03	5293 (27, 6435)	34278 (10781, 123962) †	0.02
N501Y	8196 (5721, 10486)	5203 (2513, 9395)	0.03	10723 (85, 18671)	138390 (33938, 193936) †	0.02
K417N/E484K/N501Y	584 (136, 1342)	330 (68, 1565)	0.06	1913 (327, 5033)	18306 (8513, 123734) †	0.02
K417N E484Q	4310 (1429, 8049)	1524 (388, 6947)	0.02	8780 (20, 10401)	74318 (18926, 147037) †	0.02
Δ69-70/Δ144 NTD	7101 (3184, 13363)	4696 (2134, 10782)	0.12	8607 (82, 10133)	129870 (95337, 838793) †	0.02
L18F/D80A/D215G/Δ242-244	628 (286, 6198)	771 (316, 7021)	0.88	1697 (66, 5554)	67231 (20100, 154028) †	0.02

^a Wilcoxon matched-pairs signed-rank test.

†p<.001, Wilcoxon rank-sum test to compare adults with no vaccination vs. adults with vaccination at 6-month follow-up.




Figure S1. Incidence of COVID-19 in Indiana during the study period

Neutralizing Antibody

Wild type SARS-CoV-2 antigens

nAb


Full Length Spike (ST4)

RBD1

RBD2

NCP

NTD



Spike variant antigens

E484Q


N501Y

K417N/E484K/N501Y

K417N/E484Q

Δ d69-70/ Δ 144 NTD

L18F/D80A/D215G/ Δ 242-244




Time point (0- and 6-month follow-up), by cohort

— Symptomatic, PCR+, n=8 — Symptomatic, PCR- or not tested, n=27 — Asymptomatic, known exposure, n=13 — Asymptomatic, no known exposure, n=19


Figure S2. Titer levels at study baseline and 6-month follow-up in children, according to study cohort. Line and error bars represent median and interquartile range. Titers compared by visit using Wilcoxon matched-pairs signed-rank test; *p<.05, ** p<.01, *** p<.001.

Neutralizing Ab

Wild type SARS-CoV-2 antigens



Spike variant antigens



Time point (0- and 6-month follow-up), by vaccination status

Figure S3. Titers at study baseline and 6-month follow-up in SARS-CoV-2 PCR-positive, symptomatic adults with no vaccination after visit 1 (NV, n=16) and those vaccinated after visit 1 (V, n=7). Red dots and line represent median of titers. Titers compared by visit using Wilcoxon matched-pairs signed-rank test and by age group using Wilcoxon rank-sum test; *p<.05, **p<.01. Antigen definitions included in methods section.